Elanco Animal Health Incorporated ELAN
General analysis — not personal advice.
Two new catalysts (Befrena launch and a potential demand tailwind tied to screwworm response products) could affect revenue mix and near-term sales, but uptake, margin impact, and competitive response remain uncertain.
This picture changes. Follow Elanco Animal Health Incorporated free — email when the signal or risk changes + a Sunday weekly brief.
Follow Elanco Animal Health Incorporated freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Price & valuation
Why NEUTRAL?
- Wait/hold until more datapoints emerge (e.g., early Befrena demand signals and Q2 earnings updates).
Recent News
- Since 2026-05-06, Elanco has (1) begun a phased U.S. launch of Befrena (tirnovetmab), an anti-IL-31 mAb for canine allergic/atopic dermatitis, and (2) communicated support/product offerings to address New World Screwworm following the first case in Texas. The stock traded back into the mid-$20s range in early June.
Catalysts
New World Screwworm response in Texas
What Firelda Watch includes for Elanco Animal Health Incorporated
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — AI roundup of the week's news
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Own Elanco Animal Health Incorporated? Create a free account and follow up to 3 companies — change history, weekly brief, and email when the picture changes. Upgrade to Watch for more slots and same-day alerts.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more